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Abstract Apart from the historical and clinical relevance
of positron emission tomography (PET) with 18F-
fluorodeoxyglucose (18F-FDG), various other new trac-
ers are gaining a remarkable place in functional imaging.
Their contribution to clinical decision-making is irre-
placeable in several disciplines. In this brief review we
aimed to describe the main non-FDG PET tracers based
on their clinical relevance and application for patient
care.
Keywords Positron emission tomography.Hybrid PET/
CT.Functional imaging.PET tracers.Non-FDG
Introduction
The introduction of molecular imaging and the recent
development of hybrid systems, in which both functional
and morphological information are acquired simultaneously
and can therefore be registered accurately, has led to a great
step forward in diagnostic imaging. Positron emission
tomography (PET) has paved the way for the introduction
of PET/computed tomography (CT). These machines have
been available since the last decade of the twentieth century
[1], and PET/magnetic resonance imaging (MRI) machines
are likely to be available in the near future.
Currently, 18F-fluorodeoxyglucose (18F-FDG) repre-
sents the prevailing tracer utilised in PET imaging. For this
tracer oncology is undoubtedly the most important field of
application, but other clinical fields in which 18F-FDG
plays an important role include neurology and cardiology.
The main disadvantage of 18F-FDG is that it is not a
specific oncological tracer, as several malignancies [i.e.
prostate cancer, hepatocellular carcinoma (HCC), renal cell
carcinoma, etc.] cannot be adequately assessed by 18F-
FDG-PET. Therefore other new radiopharmaceuticals have
been developed that are capable of giving more specific
information, leading to a better sensitivity and specificity or
just complementing 18F-FDG-PET results (Fig. 1).
At present a very wide variety of non-FDG-PET tracers
have been studied. Some of them are already used in
clinical practice, while others are still undergoing investi-
gation in clinical and preclinical trials. In this paper, we will
focus on some of them by selecting the principal non-FDG-
PET tracers on the basis of their clinical relevance and
application (Table 1).
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(11C-choline)
11C-Choline and its fluorinated analogue (18F-fluorocholine),
as precursors for the biosynthesis of cellular membrane
phospholipids (i.e. phosphatidylcholine), represent specific
PET tracerscapableofmarkingout membranemetabolismand
turnover. These processes are both known to be increased in
tumour cells [2]. The two tracers show no significant
difference in diagnostic performance and biodistribution,
except for the earlier urinary appearance of 18F-choline,
probably due to an incomplete tubular reabsorption [3].
For many tumour types, choline-PET is reported to be a
good diagnostic technique, although in practice its clinical
value is mainly limited to prostate cancer [4].
For staging purposes, 11C-choline has been utilised in
selected high-risk patients (high levels of PSA or Gleason
score), with the intent to assess extra-prostatic nodal and
bone metastases. For N- and M-staging, 11C-choline-PET
performs better than clinical nomograms [5]: it has a
patient-based sensitivity and specificity of 60.0% and
97.6% respectively, and a nodal-based sensitivity and
specificity of 41.4% and 99.8% respectively [6], whereas,
for staging of the primary prostate cancer (T-staging),
choline-PET is not suitable [6–8].
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Fig. 1 Maximum intensity pro-
jection (MIP) images of six
different PET tracers and their
normal distribution: (a) 18F-
fluorodeoxyglucose (18F-FDG);
(b) 11C-choline; (c) 11C-
methionine; (d 18F-dihydroxy-
phenylalanine (18F-DOPA); (e)
68Ga-DOTA-1-NaI3-octreotide
(68Ga-DOTA-NOC); (f) 11C-
acetate
374 Insights Imaging (2010) 1:373–385Table 1 Main non-FDG-PET tracers and their principal indications
Tracer Metabolic
process
Diagnostic
imaging
Oncological
indications
Clinical value
11C-Choline Cellular membrane
turnover
Prostate cancer Diagnosis/Biopsy
guidance
Identification of carcinoma foci in
patients with multiple negative biopsies
18F-Choline
(FCH)
Phosphatidylcholine
metabolism
Other tumours: Staging Assessment of proper disease extent in
high-risk patients
Bladder cancer Suspect of relapse Early detection of relapse in patients with
biochemical failure
Brain tumours, etc. Restaging Therapeutic management in patients with
documented carcinoma relapse
11C-Methionine Amino acid
transport
and protein synthesis
Brain tumours Diagnosis Differential diagnosis between benign and
malignant lesions/Inconclusive CIT
Other tumours: Grading Direct correlation between 11C-methionine
uptake and tumour grading
Head and neck, etc. Stereotactic biopsy Detection of more suitable sites for brain
biopsy
Non-oncologic indication: Treatment
response/
Prognostic value
Assessment of treatment efficacy/Direct
correlation between uptake decline and
patient outcome
Hyperparathyroidism Suspect of relapse
or residual disease
Characterisation of suspect or inconclusive
lesions at CIT
18F-DOPA Dopamine uptake
and metabolism
Neuroendocrine tumours
(NET)
Diagnosis/
Unknown primary
Diagnosis of NET/Documented NET
metastasis in unknown primary
Non-oncological indications: Staging/restaging Assessment of disease extent before
treatment
Congenital hyperinsulinism Suspect of relapse Early identification of relapse
Parkinson
68Ga-DOTA-
peptides
Somatostatin
receptors
Neuroendocrine tumours
(NET)
Diagnosis Diagnosis of NET
Other tumours: Unknown primary Identification of primary tumour in
patients with documented NET metastasis
Pheochromocytoma Staging/restaging Assessment of disease extent before
treatment
Paraganglioma Suspect of relapse Early identification of relapse
Microcytoma Treatment response Assessment of treatment efficacy
11C-Acetate Lipid synthesis and
energetic metabolism
Prostate cancer Similar to 11C-choline indications for prostate cancer
HCC Diagnosis of HCC Differential diagnosis between
benign and malignant hepatic lesions
Non-oncological indications: Staging/restaging
HCC
Assessment of disease extent
Myocardial metabolism Suspect of relapsed
HCC
Characterisation of suspect or
inconclusive lesions at CIT
18F-FLT Cellular proliferation
and
Lymphoma Diagnosis/
Primary
tumour
Differential diagnosis between benign
and malignant lesions/T staging
TK-1
activity
Lung Treatment
response
evaluation
Treatment response assessed with
FLT-PET correlates with pathological
response
Colorectal cancer
Gastric and pancreatic
18-NaF Bone metabolism Bone metastasis Diagnosis Identification of bone metastasis
Non-oncological indications: Staging Detection of bone involvement in
tumours with elevated risk of bone
metastasis
Insights Imaging (2010) 1:373–385 375The main indication for using choline-PET remains the
evaluation of prostate cancer relapse in previously treated
(radical prostatectomy or external beam radiotherapy)
patients, who present with a rising PSA serum level [9].
PET performance in this case is reported to be superior to
other conventional imaging techniques (CIT) leading to
early identification of both nodal and extranodal lesions, as
well as local recurrence (Fig. 2)[ 10–13].
The detection rate of choline-PET, however, can still be
low during restaging, especially for low PSA values [12];
therefore, PSA kinetics has been studied. Utilising trigger
PSA, PSA velocity and PSA doubling time [9, 14],
increases the performance of the method significantly and
gives clinicians useful information for a better assessment
of treatment strategies and patient follow-up.
Malignancies other than prostate cancer have been
studied with choline-PET, such as bladder cancer, brain
tumours and multiple myeloma [4, 15]. The late urinary
excretion, characterising 11C-choline, and the low back-
ground activity in the pelvic area are the main reasons for
the successful use of choline-PET in bladder cancer [4]. In
the other tumours, such as brain neoplasia or multiple
myeloma, the utility is still questioned and there does not
seem to be much improvement in diagnostic accuracy
compared with other PET tracers, such as 11C-methionine
for brain tumours and 18F-FDG for multiple myeloma
[15].
Amino acid and protein metabolism
(11C-methionine)
Methionine is an essential amino acid and the uptake of its
carbon-11 labelled form (11C-methionine) directly reflects
a m i n oa c i dt r a n s p o r ta n dp rotein metabolism. These
processes are known to be significantly increased in
malignant cells as a consequence of the increased cellular
proliferation activity [16].
The imaging potentialities of 11C-methionine as an
oncological PET tracer have already been documented in
different malignancies like brain tumours, breast cancer and
head and neck tumours [17–19].
11C-Methionine has a main advantage in brain imaging
compared with 18F-FDG: there is almost no tracer uptake
in normal brain tissue. On the other hand, malignant lesions
show a significantly increased uptake of 11C-methionine,
with an optimal tumour-to-background ratio. Also, other
benign conditions, such as fibrosis, necrosis or oedema,
which usually reduce FDG-PET specificity, show a rela-
tively low uptake with methionine-PET. For these reasons,
methionine-PET is predominantly used for the detection of
brain tumours [20].
The good correlation that has been reported among the
Ki-67 index, proliferating cell nuclear antigen expression
and methionine uptake is used to give preliminary
information on tumour grading (low- versus high-grade
lesions) and provide a reliable initial prognostic value
[21–23].
In gliomas, methionine-PET is reported to have good
sensitivity and specificity, 89% and 100% respectively, and
this can determine a change in treatment management in up
to 50% of the cases. However, during acute inflammation
and in low-grade forms the diagnostic performance can be
suboptimal (sensitivity range 65-85%) [24, 25].
The good diagnostic performance of methionine-PET is
mostly maintained in the case of post-treatment evaluation
and during follow-up, when tumour recurrence is suspected
[26]: sensitivity, specificity in detecting tumour recurrence
range from 77.8 to 100% and 60% to 100%, respectively
[26]. In recurrent disease, methionine-PET has a major
advantage over conventional imaging techniques (including
MRI) as it can make a proper differential diagnosis between
malignant lesions and other non-pathological findings (i.e.
Table 1 (continued)
Tracer Metabolic
process
Diagnostic
imaging
Oncological
indications
Clinical value
Orthopaedic pathological
conditionsOrthopaedic
pathological conditions
18F-FMISO Tumour hypoxia Solid tumours Pre-treatment
assessment
Detection of hypoxic quota in
malignant tissue for prognostic
value and treatment intensity modulation
18F-FAZA
18F-EF3 and 5
64Cu-ATSM
CIT conventional imaging technique
HCC hepatocellular carcinoma
376 Insights Imaging (2010) 1:373–385infection, infarction and haemorrhage) or other brain tissue
changes induced by previous surgical handling or external
beam radiotherapy (Fig. 3)[ 23, 27].
The ability of methionine-PET to distinguish accurately
between malignant tissue and necrotic areas, combined with
the better delineation of tumour volumes, has found a
proper use for radiotherapy planning and can be of help for
stereotactic brain biopsy too [28].
Dopamine uptake and metabolism
(18F-DOPA)
18F-Dihydroxyphenylalanine (18F-DOPA) was first intro-
duced as a marker for imaging dopamine uptake and
metabolism in basal ganglia [29]. Afterwards, this tracer
was applied for the detection of malignancies such as brain
tumours [30], neural crest derived (neuroendocrine) neo-
plasms [31], and other conditions like congenital hyperin-
sulinism [32].
The rationale for imaging neuroendocrine with 18F-
DOPA PET is the ability of these tumours to accumulate
and decarboxylate L-DOPA as a precursor of dopamine in
the catecholamine pathway [33]. The increased L-DOPA
transport within the cells by the large amino acid
transporter system (LAT) and the increased activity of L-
DOPA decarboxylase (AADC) documented in neuroendo-
crine tumours (NET) [34], the high signal-to-background
ratio and the good spatial resolution of the PET camera
system, permit the detection of both primary and metastatic
lesions in many neuroendocrine malignancies. Examples
for which 18F-DOPA PET imaging has proved to be
successful are carcinoids, gastro-entero-pancreatic neuroen-
MIP 
Transaxial images 
Fig. 2 11C-Choline PET in a
patient with biochemical failure
after radical prostatectomy: MIP
and transaxial images document
both lymph nodal (arrows) and
bone relapse (arrowhead)
Insights Imaging (2010) 1:373–385 377docrine tumours, glomus tumour, medullary thyroid, neu-
roblastoma, paraganglioma (glomus tumour) and phaeo-
chromocytoma. [31, 35–37].
In neuroendocrine tumours with elevated catecholamine
release, such as phaeochromocytomas, 18F-DOPA PET
shows the best performance, with sensitivity and specificity
rates of 84.6% and 100% respectively (Fig. 4)[ 36].
Moreover, its diagnostic accuracy for the detection of
carcinoids [31, 37] and phaeochromocytoma [31, 36] was
shown to be higher than that of other imaging techniques,
ab
Fig. 3 11C-Methionine PET in
two different patients previously
operated on for glioma: (a)
residual disease at the level of
the surgical crater; (b) glioma
recurrence in the contralateral
brain hemisphere
378 Insights Imaging (2010) 1:373–385both morphological (including CT/MRI) and functional
(123I-MIBG and 111In-Octreoscan) [31, 38].
Somatostatin receptors
(68Ga-DOTA-NOC and other analogues)
An important characteristic of neuroendocrine tumours is
the expression of somatostatin receptors on their cell
membrane. Thus far, five somatostatin receptor subtypes
have been discovered: SSTR1–5. The SSTR2, SSTR3 and
SSTR5 subtypes in particular [39] are often overexpressed
on the cell membranes of neuroendocrine tumours (on
average in 80–90% of cases).
The discovery of the overexpression of the somatostatin
receptors in neuroendocrine tumours led to the develop-
ment of radiolabelled somatostatin analogues. For decades,
111In-octreotide (Octreoscan) has been considered the
“gold standard” for imaging and staging neuroendocrine
tumours [40], but recently new PET tracers have been
developed for imaging somatostatin receptors in NETs.
These radiopharmaceuticals carry a somatostatin analogue
labelled with the positron emitting radionuclide 68Ga,
which is easily obtainable by a portable 68Ge/68Ga
generator.
In 2001, the first 68Ga-DOTA somatostatin analogues
were developed for clinical purposes [41] and up to now
several 68Ga-DOTA-peptides have been reported. The
majority show a similar affinity for SSTR2 and 5, whereas
68Ga-DOTA-NOC has also demonstrated a high affinity for
SSTR3 [42, 43].
In the literature, 68Ga-DOTA-peptides are reported to be
excellent candidates for imaging and staging patients with
MIP image 
Transaxial images 
Fig. 4 18F-DOPA PET in a
patient affected by pheochro-
mocytoma of the right adrenal
gland (arrow); physiological
uptake of the tracer in the
gallbladder (arrowhead)
Insights Imaging (2010) 1:373–385 379neuroendocrine tumours, including the localisation of
primary tumours in patients with known NET metastasis
(carcinoma of unknown primary origin) (Fig. 5)[ 44, 45].
Sensitivity and specificity are documented as 97-100% and
96-100% in different papers [46, 47] and in a large series
the diagnostic accuracy was reported to be higher than that
of CT, 111In-octreotide or other PET tracers, such as 18F-
DOPA [46, 48, 49]. PET with 68Ga-DOTA-peptides gave
additional information to other instrumental investigations
in 21.4% of the cases and led to a change in therapeutic
management in 14% of cases [46, 47].
In addition, PET with 68Ga-DOTA-peptides gives
useful information on therapeutic work-up, by providing
clinicians with important pre- and post-therapeutic data
on tracer uptake and receptor expression. 68Ga-DOTA-
peptide uptake value (SUVmax) has been demonstrated
to correlate with clinical and pathological features in
NET, by also resulting in an accurate prognostic factor
for patient outcome [50]. As already reported by Gabriel
et al. [46, 51], it also gives a preliminary estimation of
receptor expression, thus permitting selection of patient
candidates for peptide receptor radionuclide therapy
(PRRT) and selection of which therapeutic agent to use
(90Y-DOTATOC or 177Lu-DOTATATE).
Lipid synthesis and energetic metabolism
(11C-acetate)
11C-Acetate is a two-way tracer that can physiologically
cover two different metabolic pathways: one is the pathway
MIP image 
Transaxial images 
Fig. 5 68Ga-DOTA-NOC PET
in a patient with local recurrence
of NET after distal pancreasec-
tomy and splenectomy (arrow
and arrowhead)
380 Insights Imaging (2010) 1:373–385leading to the synthesis of cholesterol and fatty acids,
which are then incorporated into cellular membrane [52],
the other one involves energy metabolism via the tricar-
boxylic acid (TCA) cycle, used either for catabolic or
anabolic purposes [53].
The energy pathway was the first one to be utilised for
PET imaging with 11C-acetate, and consisted of cardiac
studies on the assessment of myocardial blood flow and
oxidative metabolism [54]. More recently, acetate-PET has
been used in oncology too, for the assessment of some
tumours, such as prostate cancer, renal cell carcinoma or
HCC, in which FDG-PET is of limited use [55–57]. In
those tumours, there is an increased uptake of 11C-acetate
related to the over-expression of fatty acid synthetase, a key
enzyme that entraps 11C-acetyl-CoA within different
cellular structures and pathways [58].
In clinical practice, acetate-PET has a major application
in imaging prostate cancer and HCC [55, 56].
In prostate cancer, 11C-acetate PET has similar indica-
tions to choline-PET and up to now no significant
difference in diagnostic accuracy has been found between
the two tracers [59]. Acetate-PET can be used from the
diagnosis to staging/restaging of prostate cancer [60, 61],
with major indications in previously treated patients
presenting with biochemical failure [55, 62].
11C-Acetate has also found a proper application in the
detection of HCC, which usually shows a low FDG uptake,
secondary to the lower glycosidic metabolism of tumoral
cells, compared with normal liver parenchyma [56, 63].
Acetate-PET has demonstrated a good sensitivity (83-
87.3%) in the detection of HCC, especially in well-
differentiated forms (Fig. 6)[ 63]. FDG-PET maintains a
role in dedifferentiated HCC, but overall accuracy amelio-
rates when associating 18F-FDG and 11C-acetate PET,
thanks to the complementary information the two metabolic
tracers can give [63, 64].
Proliferation
(18F-FLT)
Introduced in 1998, 18F-fluorothymidine (18F-FLT) [65]i s
utilised in oncology as a marker of cellular proliferation.
More precisely, 18F-FLT is entrapped in cells during the S-
phase and its uptake correlates with the activity of thymidine
kinase-1 (TK-1), a key enzyme that is up-regulated during
DNA synthesis and cellular growth [65, 66].
The first attempts made to estimate proliferation activity
in cells started almost three decades ago with 11C-
thymidine, but 18F-FLT, which is derived from the
cytostatic drug zidovudine [65, 67], seems to be the most
suitable tracer for PET imaging.
In oncology FLT-PET is used for several malignancies,
such as lung, oesophageal, gastric and pancreatic tumours,
gliomas, sarcomas and lymphomas [68–71], and its uptake
in tumour cells is documented to directly correlate with Ki-
67 immunohistochemistry [71].
a b
cd
Fig. 6 Transaxial images of a
patient affected by recurrent
hepatocarcinoma in the para-
caval region (arrow): (a) CeCT;
(b) 11C-acetate PET images; (c)
fused PET/CT images; (d)
localisation CT
Insights Imaging (2010) 1:373–385 381FLT-PET has a good signal-to-background rate, but the
tracer is physiologically taken up in bone marrow and
hepatic parenchyma, making these tissues difficult to
investigate with 18F-FLT [67].
Compared with 18F-FDG uptake, 18F-FLT on average
shows a lower accumulation in malignant tissue [68] and
the method itself appears less accurate than FDG-PET for
staging and restaging evaluation. However 18F-FLT is a
more specific oncological tracer than 18F-FDG and can
show a good sensitivity in the detection of primary tumour
[68, 72]. As a marker of tumour cell proliferation, 18F-FLT
also appears to be more accurate than 18F-FDG in
treatment evaluation, by reflecting directly tumoral biolog-
ical response [71].
Bone metabolism
(18F-NaF)
Thanks to the broad availability of 18F, the extremely
simple synthesis of the tracer and the frequent shortage of
99mTc, PET imaging with 18F-Fluoride (18F-NaF) may
represent the future of bone imaging. Similar to 99mTc-
radiolabelled diphosphonates, 18F-NaF uptake reflects
osteoblastic metabolism, thanks to the physiological incor-
poration of fluoride in bone matrix as fluoroapatite [73].
However, imaging with 18F-NaF has some major advan-
tages over bone scintigraphy, which are related to a more
rapid tracer uptake: images can be available immediately
after injection, with better image quality; high image
resolution is achieved, especially in hybrid PET/CT
acquisitions, thanks to an optimal signal-to-background
ratio [74].
In several malignancies, such as prostate cancer, lung
and breast tumours, PET with 18F-fluoride has demonstrat-
ed a significantly higher diagnostic accuracy compared with
bone scintigraphy [75, 76], by reaching maximal rates
(100%) of sensitivity and specificity versus 92% and 82%
respectively for 99mTc-MDP scintigraphy [77].
Fluoride-PET shows an elevated sensitivity for both
sclerotic and lytic lesions [77, 78], but this high sensitivity
rate outlines the principal drawback of the tracer: 18F-
fluoride is not a specific oncological tracer, thus sometimes
it can be difficult to differentiate between benign and
malignant lesions. However combined morphological and
functional imaging, as in hybrid PET/CT systems, and the
clever recycling of the tracer cocktails concept [79] may
help to overcome potential false-positive findings.
Similar to conventional bone scintigraphy, 18F-NaF can
also be utilised in other fields of interest related to benign
pathological bone conditions, such as orthopaedic problems
[80].
Tumour hypoxia and oxygen metabolism
(18F-FMISO and other tracers)
Tumour hypoxia and oxygen metabolism represent a major
task in oncology, and functional imaging with PET can
make a remarkable contribution to patient management and
therapeutic decisions. It is well known that tumour response
to treatment is significantly related to the level of tumour
oxygenation and the quota of hypoxic tissue [81].
The first PET tracer introduced for imaging tumour
oxygenation was 18F-fluoromisonidazole (18F-FMISO)
[82]. Initially utilised in nuclear cardiology for imaging
myocardial ischaemia, the tracer was subsequently intro-
duced into oncology for imaging several malignancies, such
as lung cancer, sarcomas, brain tumours and head and neck
cancers [83, 84].
The presence of a suboptimal signal-to-background ratio
and the lack of 18F-FMISO uptake in necrotic tissue led to
the development of further hypoxic tracers. This is the case
for 18F-fluoroazomycin arabinozide (18F-FAZA) [85],
18F-fluoronitroimidazole (18F-EF3 and 5) [86, 87]o r
64Cu-methylthiosemicarbazone (64Cu-ATSM) [88, 89].
All these tracers give remarkable information on imaging
tumour hypoxia, although thanks to an optimal biodistri-
bution and a high signal-to-background ratio, the most
promising one seems to be 64Cu-ATSM. This tracer has
already demonstrated good prognostic values in different
tumours, including lung and cervical cancers [87–89].
Conclusions
This brief outlook provides only a short overview of non-
FDG PET tracers and their use in a clinical setting. The
potential list of tracers is continuously increasing in number
and new applications can hopefully be introduced. The
development of fused imaging, where anatomical and
functional data are combined, has given diagnostic imaging
“new eyes” for old and new indications.
Thanks to the broader availability of PET imaging, the
increasing interest and development of molecular imaging
and hybrid technology, the future of diagnostic imaging
faces no obstacles but mankind’s awareness and common
sense.
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